GlassScriptPhysician profile
David S Altman
NPI 1669469458
$3,827.13
in general payments reported to CMS, 2019-2025
37 companies · $819 in 2025
The $819 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $161 · 2021: $61.25 · 2022: $194 · 2023: $1,080 · 2024: $825 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.81 |
| Education | $159.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $782.38 | 2019-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $480.06 | 2019-2025 | Erleada |
| Dentsply Ih Ab | $359.52 | 2023-2025 | Lofric, Lofric |
| Teleflex LLC | $243.62 | 2024-2025 | Urolift |
| Bayer Healthcare Pharmaceuticals INC. | $222.27 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $165.30 | 2023-2025 | Gemtesa, Orgovyx |
| Myriad Genetic Laboratories, INC. | $147.13 | 2023-2024 | Prolaris |
| Pfizer INC. | $122.53 | 2019-2025 | |
| Neotract INC. | $119.37 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $99.88 | 2024-2025 | Adstiladrin |
| Abbvie INC. | $99.13 | 2019-2024 | Lupron Depot |
| Dentsply Ih INC. | $93.98 | 2020-2022 | |
| 180 Medical, INC. | $85.93 | 2024-2025 | |
| Procept Biorobotics Corporation | $78.74 | 2024-2025 | Aquabeam System |
| Merck Sharp & Dohme LLC | $74.81 | 2022-2023 | Lynparza, Keytruda |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $59.34 | 2022-2023 | |
| Axonics, INC. | $53.73 | 2023-2024 | Axonics |
| Civco Medical Instruments | $44.61 | 2025 | |
| Convatec INC. | $44.12 | 2022 | |
| Progenics Pharmaceuticals, INC. | $43.26 | 2023 | Pylarify |
| Amgen INC. | $39.58 | 2019 | |
| Calliditas Therapeutics US INC. | $34.35 | 2025 | Tarpeyo |
| Laborie Medical Technologies Corp. | $31.33 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Coloplast Corp | $29.76 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $29.34 | 2025 | Jynarque |
| Endo Pharmaceuticals INC. | $29.11 | 2019-2020 | |
| Olympus America INC. | $23.75 | 2025 | Itind System |
| Ambu INC. | $22.95 | 2024 | |
| Rochester Medical Corporation | $22.18 | 2019 | |
| Boston Scientific Corporation | $21.39 | 2022 | |
| Dendreon Pharmaceuticals LLC | $20.32 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $19.29 | 2019 | |
| Cook Medical LLC | $18.53 | 2019 | |
| Telix Pharmaceuticals | $17.55 | 2023 | Illuccix |
| Alnylam Pharmaceuticals INC. | $17.17 | 2023 | Oxlumo |
| Immunitybio, INC. | $15.75 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.07 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Altman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.